Endocyte to Present at the 2013 Credit Suisse Healthcare Conference

WEST LAFAYETTE, Ind., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Ron Ellis, president and CEO of Endocyte, will present at the 2013 Credit Suisse Healthcare Conference on Wednesday, Nov.13, at 8:30 a.m. MST. The conference will be held at The Phoenician Hotel in Phoenix, Arizona.

A live audio webcast of the Company's presentation can be accessed under "Events & Presentations" in the Investor Relations section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event and a replay will be available on the Company's website for 90 days following the conference.

About Endocyte

Endocyte is a biopharmaceutical company and leader developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte's website at www.endocyte.com.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc. (212) 362-1200 stephanie@sternir.com Martina Schwarzkopf, Ph.D., Russo Partners (212) 845-4292 martina.schwarzkopf@russopartnersllc.com Tony Russo, Ph.D., Russo Partners (212) 845-4251 tony.russo@russopartnersllc.comSource:Endocyte, Inc.